Research Papers:

Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer

Qiang Sun _, Shixin Zhou, Jingjing Zhao, Changwen Deng, Ruidi Teng, Yiding Zhao, Jiajia Chen, Jiebin Dong, Ming Yin, Yun Bai, Hongkui Deng and Jinhua Wen

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:13694-13705. https://doi.org/10.18632/oncotarget.24122

Metrics: PDF 2105 views  |   HTML 3471 views  |   ?  


Qiang Sun1, Shixin Zhou1, Jingjing Zhao1, Changwen Deng1, Ruidi Teng1, Yiding Zhao1, Jiajia Chen1, Jiebin Dong1, Ming Yin2, Yun Bai1, Hongkui Deng1,3,4 and Jinhua Wen1

1Department of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

2Beijing Vitalstar Biotechnology Co., Ltd., Beijing, China

3The MOE Key Laboratory of Cell Proliferation and Differentiation, College of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

4Shenzhen Stem Cell Engineering Laboratory, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China

Correspondence to:

Jinhua Wen, email: [email protected]

Hongkui Deng, email: [email protected]

Yun Bai, email: [email protected]

Keywords: adoptive cell therapy; mesothelin; CAR; lung metastasis

Received: May 16, 2017     Accepted: November 13, 2017     Published: January 10, 2018


Pancreatic cancer is known as one of the most lethal cancers in the world. A majority of advanced stage pancreatic cancer patients are diagnosed with distant metastasis and given poor prognoses, calling for a better therapeutic option. Mesothelin, which is overexpressed in pancreatic cancer and other solid tumors, is a potential target for pancreatic cancer immunotherapy. Adoptive transfer of T cells engineered with chimeric antigen receptors (CART cells) was effective for treating CD19-positive leukemia, but it is more difficult for CART cells to eliminate solid tumors. Because distal metastasis is an important malignant behavior of solid tumors, we investigated whether meso-CART cells exert anti-tumor effects against distant metastases. After expressing meso-CAR in human primary T lymphocytes, the resultant meso-CART cells released cytokines in response to and exhibited cytolytic effects on mesothelin-positive tumor cells in vitro. Injection of meso-CART cells into tumor-bearing mice moderately delayed subcutaneous tumor growth and eliminated lung metastases. This is the first study to show that meso-CART cells are effective against lung metastases induced by intravenous injection of pancreatic tumor cells. Our results suggest that meso-CART cells may be an effective clinical treatment for mesothelin-positive primary and metastatic tumors in pancreatic cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24122